Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEINS: Sulodexide for leg symptoms in chronic venous disease
2020-000110-15Phase 3Completed
- Sponsor
- Alfasigma
- Start
- Jan 2021
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic venous disease (CVD) comparing Sulodexide with Placebo (2 arms). Primary endpoint: Change from baseline in leg symptom intensity at end of treatment. Started Jan 2021; status: completed.
02
Drugs
sulodexide
03
Conditions
chronic venous disease (CVD)
Beyond the preview
Go deeper on 2020-000110-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000110-15.